Pneumocystis jirovecii pneumonia

Palella FJ, Delaney KM, Moorman FC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998 Mar 26;338(13):853-60.Full text  Abstract

National Institutes of Health; Centers for Disease Control and Prevention; HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society; American Academy of Pediatrics. Guidelines for the prevention and treatment of opportunistic infections in childrenwith and exposed to HIV: Pneumocystis jirovecii pneumonia. 2013 [internet publication].Full text

Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Pneumocystis jirovecii pneumonia. Mar 2019 [internet publication].Full text

Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018 Oct 20;36(30):3043-54.Full text  Abstract

Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238.Full text  Abstract

Fishman JA, Gans H, AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13587. Abstract

Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011 Jan 1;183(1):96-128.Full text  Abstract

Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015 Apr 2;(4):CD006150.Full text  Abstract

Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014 Dec;44(12b):1350-63.Full text  Abstract

Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016 Sep;71(9):2397-404.Full text  Abstract

Classen AY, Henze L, von Lilienfeld-Toal M, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol. 2021 Jun;100(6):1603-1620.Full text  Abstract

1. Palella FJ, Delaney KM, Moorman FC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998 Mar 26;338(13):853-60.Full text  Abstract

2. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the US in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000 Apr;30(suppl 1):S5-14.Full text  Abstract

3. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004 Oct;10(10):1713-20. Abstract

4. Low A, Gavriilidis G, Larke N, et al. Incidence of Opportunistic Infections and the Impact of Antiretroviral Therapy Among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016 Jun 15;62(12):1595-1603.Full text  Abstract

5. Limper AH, Adenis A, Le T, et al. Fungal infections in HIV/AIDS. Lancet Infect Dis. 2017 Nov;17(11):e334-43.Full text  Abstract

6. Kolbrink B, Scheikholeslami-Sabzewari J, Borzikowsky C, et al. Evolving epidemiology of pneumocystis pneumonia: Findings from a longitudinal population-based study and a retrospective multi-center study in Germany. Lancet Reg Health Eur. 2022 Jul;18:100400.Full text  Abstract

7. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet. 1999 Apr 17;353(9161):1293-8. Abstract

8. Buchacz K, Lau B, Jing Y, et al. Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000-2010. J Infect Dis. 2016 Sep 15;214(6):862-72.Full text  Abstract

9. Turvey SL, Bagshaw SM, Eurich DT, et al. Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy. Can J Infect Dis Med Microbiol. 2017;2017:7868954.Full text  Abstract

10. Kim JH, Psevdos G Jr, Gonzalez E, et al. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART). Infection. 2013 Apr;41(2):545-51. Abstract

11. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990 Jan 18;322(3):161-5. Abstract

12. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med. 1997 Jan;155(1):60-6. Abstract

13. Pulvirenti J, Herrera P, Venkataraman P, et al. Pneumocystis carinii pneumonia in HIV-infected patients in the HAART era. AIDS Patient Care STDS. 2003 Jun;17(6):261-5. Abstract

14. Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS. 2000 Nov 10;14(16):2559-66. Abstract

15. Huang L, Hecht FM. Why does Pneumocystis carinii pneumonia still occur? AIDS. 2000 Nov 10;14(16):2611-2. Abstract

16. López-Sánchez C, Falcó V, Burgos J, et al. Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era:experience in a university hospital and review of the literature. Medicine (Baltimore). 2015 Mar;94(12):e681.Full text  Abstract

17. Centers for Disease Control and Prevention (CDC). HIV prevalence estimates: United States, 2006. MMWR Morb Mortal Wkly Rep. 2008 Oct 3;57(39):1073-6.Full text  Abstract

18. Fisk DT, Meshnick, S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis. 2003 Jan 1;36(1):70-8. Abstract

19. B-Lajoie MR, Drouin O, Bartlett G, et al. Incidence and Prevalence of Opportunistic and Other Infections and the Impact of Antiretroviral Therapy Among HIV-infected Children in Low- and Middle-income Countries: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016 Jun 15;62(12):1586-1594.Full text  Abstract

20. Nesheim SR Kopogiannis BG, Soe SM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics. 2007 Jul;120(1):100-9. Abstract

21. Kovacs A, Frederick T, Church J, et al. CD4 T-lymphocyte counts and Pneumocystis carinii pneumonia in pediatric HIV infection. JAMA. 1991 Apr 3;265(13):1698-703. Abstract

22. National Institutes of Health; Centers for Disease Control and Prevention; HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society; American Academy of Pediatrics. Guidelines for the prevention and treatment of opportunistic infections in childrenwith and exposed to HIV: Pneumocystis jirovecii pneumonia. 2013 [internet publication].Full text

23. Lowe DM, Rangaka MX, Gordon F, et al. Pneumocystis jirovecii pneumonia in tropical and low and middle income countries: a systematic review and meta-regression. PLoS One. 2013;8(8):e69969.Full text  Abstract

24. Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007 May;26(5):663-70. Abstract

25. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996 Jan;71(1):5-13. Abstract

26. Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014 Dec;127(12):1242.e11-7. Abstract

27. Bienvenu AL, Traore K, Plekhanova I, et al. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis. 2016 May;46:11-7. Abstract

28. Ling C, Qian S, Wang Q, et al. Pneumocystis pneumonia in non-HIV children: a 10-year retrospective study. Clin Respir J. 2018 Jan;12(1):16-22. Abstract

29. Maini R, Henderson KL, Sheridan EA, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis. 2013 Mar;19(3):386-92.Full text  Abstract

30. Martin-Garrido I, Carmona EM, Specks U, et al. Pneumocystis pneumonia in patients treated with rituximab. 2013 Jul;144(1):258-65.Full text  Abstract

31. Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014 Oct 1;(10):CD005590.Full text  Abstract

32. Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Pneumocystis jirovecii pneumonia. Mar 2019 [internet publication].Full text

33. Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988 Aug 11;334(6182):519-22. Abstract

34. Stringer JR, Cushion MT, Wakefield AE. New nomenclature for the genus Pneumocystis. J Eukaryot Microbiol. 2001;(suppl):184S-9S. Abstract

35. Stringer JR, Beard CB, Miller RF, et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002 Sep;8(9):891-6.Full text  Abstract

36. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989 Nov;140(5):1204-9. Abstract

37. Leoung GS. Pneumocystosis and HIV. HIV InSite Knowledge Base. Jan 2006 [internet publication].Full text

38. Harigai M, Koike R, Miyasaka M, et al. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007 Nov 1;357(18):1874-6. Abstract

39. Imaizumi K, Sugishita M, Usui M, et al. Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis. Intern Med. 2006;45(10):685-8. Abstract

40. Kalyoncu U, Karadag O, Akdogan A, et al. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis. 2007;39(5):475-8. Abstract

41. Lahiff C, Khiaron OB, Nolan N, et al. Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis. Ir J Med Sci. 2007 Dec;176(4):309-11. Abstract

42. Mori S, Imamura S, Fiyofiji C, et al. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol. 2006;16(1):58-62. Abstract

43. Salzer HJF, Schäfer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration. 2018;96(1):52-65.Full text  Abstract

44. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015 Nov;136(5):1186-205.e1-78.Full text  Abstract

45. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegeners granulomatosis. Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):795-9. Abstract

46. Green H, Paul M, Vidal J, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clinic Proc. 2007 Sep;82(9):1052-9. Abstract

47. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018 Oct 20;36(30):3043-54.Full text  Abstract

48. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238.Full text  Abstract

49. Fishman JA, Gans H, AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13587. Abstract

50. Helweg-Larsen J, Tsolaki AJ, Miller RF, et al. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM. 1998 Dec;91(12):813-20. Abstract

51. Olsson M, Lidman C, Latouche S, et al. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol. 1998 Jun;36(6):1737-40. Abstract

52. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jiroveci transmission among 16 patients after kidney transplantation. J Clin Microbiol. 2008 Mar;46(3):966-71. Abstract

53. Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect. 2002 Jan;4(1):95-103. Abstract

54. Zheng M, Shellito JE, Marrero L, et al. CD4+ T cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest. 2001 Nov;108(10):1469-74. Abstract

55. Wells J, Haidaris CG, Wright TW, et al. Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen. Infect Immunol. 2006 Apr;74(4):2446-8. Abstract

56. Theus SA, Smulian AG, Steele P, et al. Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine. 1998 Jul;16(11-12):1149-57. Abstract

57. Cobos Jiménez V, Rabacal W, Rayens E, et al. Immunization with <i>Pneumocystis</i> recombinant KEX1 induces robust and durable humoral responses in immunocompromised non-human primates. Hum Vaccin Immunother. 2019;15(9):2075-2080.Full text  Abstract

58. Tesini BL, Wright TW, Malone JE, et al. Immunization with Pneumocystis Cross-Reactive Antigen 1 (Pca1) Protects Mice against Pneumocystis Pneumonia and Generates Antibody to Pneumocystis jirovecii. Infect Immun. 2017 Apr;85(4):.Full text  Abstract

59. Kling HM, Norris KA. Vaccine-Induced Immunogenicity and Protection Against Pneumocystis Pneumonia in a Nonhuman Primate Model of HIV and Pneumocystis Coinfection. J Infect Dis. 2016 May 15;213(10):1586-95.Full text  Abstract

60. Katz MH, Baron RB, Grady D. Risk stratification of ambulatory patients suspected of Pneumocystis pneumonia. Arch Intern Med. 1991 Jan;151(1):105-10. Abstract

61. Pareja JGR, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998 May;113(5):1215-24. Abstract

62. Singh N, Shafer RW, Swindells S (eds). HIV clinical manual. Pittsburgh, PA: ESun Technologies; 2003.

63. Fortun J, Navas E, Marti-Belda P, et al. Pneumocystis carinii pneumonia in HIV-infected patients: diagnostic yield of induced sputum and immunofluorescent stain with monoclonal antibodies. Eur Respir J. 1992 Jun;5(6):665-9. Abstract

64. Kovacs JA, Ng VL, Masur H, et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988 Mar 10;318(10):589-93. Abstract

65. Midgley J, Parsons P, Leigh TR, et al. Increased sensitivity of immunofluorescence for detection of Pneumocystis carinii. Lancet. 1989 Dec 23-30;2(8678-8679):1523. Abstract

66. Ng VL, Virani NA, Chaisson RE, et al. Rapid detection of Pneumocystis carinii using a direct fluorescent monoclonal antibody stain. J Clin Microbiol. 1990 Oct;28(10):2228-33. Abstract

67. Harcup C, Baier HJ, Pitchenik AE. Evaluation of patients with the acquired immunodeficiency syndrome (AIDS) by fiberoptic bronchoscopy. Endoscopy. 1985 Nov;17(6):217-20. Abstract

68. Zaman MK, White DA. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance. Lancet. 1988 Nov 5;2(8619):1049-51. Abstract

69. Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol. 1997 Oct;169(4):967-75. Abstract

70. Huang L, Stansell J, Osmond D, et al. Performance of an algorithm to detect Pneumocystis carinii pneumonia in symptomatic HIV-infected persons. Chest. 1999 Apr;115(4):1025-32. Abstract

71. Sankary RM, Turner J, Lipavsky A, et al. Alveolar-capillary block in patients with AIDS and Pneumocystis carinii pneumonia. Am Rev Respir Dis. 1988 Feb;137(2):443-9. Abstract

72. Shelhamer JH, Gill VJ, Quinn TC, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med. 1996 Mar 15;124(6):585-99. Abstract

73. Broaddus C, Dake MD, Stulbarg MS, et al. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Jun;102(6):747-52. Abstract

74. Fillaux J, Malvy S, Alvarez M, et al. Accuracy of a routine real-time PCR assay for the diagnosis of Pneumocystis jiroveci pneumonia. J Microbiol Methods. 2008 Oct;75(2):258-61. Abstract

75. Tuncer S, Erguven S, Kocagoz S, et al. Comparison of cytochemical staining, immunofluorescence and PCR for diagnosis of Pneumocystis carinii on sputum samples. Scand J Infect Dis. 1998;30(2):125-8. Abstract

76. Larsen HH, Masur H, Kovacs JA, et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol. 2002 Feb;40(2):490-4. Abstract

77. Helweg-Larsen J, Jensen JS, Lundgren B. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol. 1998 Jul;36(7):2068-72. Abstract

78. Larsen HH, Huang L, Kovacs JA, et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis. 2004 May 1;189(9):1679-83. Abstract

79. Skelly MJ, Holzman RS, Merali S. S-adenosylmethionine levels in the diagnosis of Pneumocystis carinii pneumonia in patients with HIV infection. Clin Infect Dis. 2008 Feb 1;46(3):467-71.Full text  Abstract

80. Summah H, Zhu YG, Falagas ME, et al. Use of real-time polymerase chain reaction for the diagnosis of Pneumocystis pneumonia in immunocompromised patients: a meta-analysis. Chin Med J (Engl). 2013;126(10):1965-73. Abstract

81. Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009 Oct 1;49(7):1128-31.Full text  Abstract

82. Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009 Apr 22;9:47.Full text  Abstract

83. Desmet S, Van Wijngaerden E, Maertens J, et al. Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol. 2009 Dec;47(12):3871-4.Full text  Abstract

84. Del Bono V, Mularoni A, Furfaro E, et al. Clinical evaluation of a (1,3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol. 2009 Oct;16(10):1524-6.Full text  Abstract

85. Nakamura H, Tateyama M, Tasato D, et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med. 2009;48(4):195-202.Full text  Abstract

86. Huang L. Clinical and translational research in pneumocystis and pneumocystis pneumonia. Parasite. 2011 Feb;18(1):3-11. Abstract

87. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012 Jan;50(1):7-15.Full text  Abstract

88. Li WJ, Guo YL, Liu TJ, et al. Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-Glucan: a bivariate meta-analysis and systematic review. J Thorac Dis. 2015 Dec;7(12):2214-25.Full text  Abstract

89. Sax PE, Komarow L, Finkelman MA, et al. Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis. 2011 Jul 15;53(2):197-202.Full text  Abstract

90. Wood BR, Komarow L, Zolopa AR, et al. Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS. 2013 Mar 27;27(6):967-72. Abstract

91. Kennedy CA, Goetz MB. Atypical roentgenographic manifestations of Pneumocystis carinii pneumonia. Arch Intern Med. 1992 Jul;152(7):1390-8. Abstract

92. Sandhu JS, Goodman PC. Pulmonary cysts associated with Pneumocystis carinii pneumonia in patients with AIDS. Radiology. 1989 Oct;173(1):33-5. Abstract

93. Abd AG, Nierman DM, Ilowite JS, et al. Bilateral upper lobe Pneumocystis carinii pneumonia in a patient receiving inhaled pentamidine prophylaxis. Chest. 1988 Aug;94(2):329-31. Abstract

94. Aberg JA. Coccidioidomycosis and HIV. HIV InSite Knowledge Base. Mar 2006 [internet publication].Full text

95. Drew WL, Lalezari JP. Cytomegalovirus and HIV. HIV InSite Knowledge Base. May 2006 [internet publication].Full text

96. Young EM, Goldman H. Histoplasmosis and HIV infection. HIV InSite Knowledge Base. Mar 2006 [internet publication].Full text

97. Krown SE. Clinical characteristics of Kaposi sarcoma. HIV InSite Knowledge Base. Feb 2006 [internet publication].Full text

98. Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011 Jan 1;183(1):96-128.Full text  Abstract

99. Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015 Apr 2;(4):CD006150.Full text  Abstract

100. Benfield T, Atzori C, Miller RF, et al. Second-line salvage treatment of AIDS-associated Pneumocystis jiroveci pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr. 2008 May 1;48(1):63-7. Abstract

101. Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014 Dec;44(12b):1350-63.Full text  Abstract

102. Wazir JF, Ansari NA. Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med. 2004 Sep;128(9):1023-7. Abstract

103. Injean P, Eells SJ, Wu H, et al. A systematic review and meta-analysis of the data behind current recommendations for corticosteroids in non-HIV-related PCP: knowing when you are on shaky foundations. Transplant Direct. 2017 Feb 15;3(3):e137.Full text  Abstract

104. Wieruszewski PM, Barreto JN, Frazee E, et al. Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome. Chest. 2018 Sep;154(3):636-644.Full text  Abstract

105. Inoue N, Fushimi K. Adjunctive Corticosteroids decreased the risk of mortality of non-HIV Pneumocystis Pneumonia. Int J Infect Dis. 2019 Feb;79:109-115.Full text  Abstract

106. Ding L, Huang H, Wang H, et al. Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies. Ann Intensive Care. 2020 Mar 20;10(1):34.Full text  Abstract

107. Fujikura Y, Manabe T, Kawana A, et al. Adjunctive Corticosteroids for Pneumocystis jirovecii Pneumonia in Non-HIV-infected Patients: A Systematic Review and Meta-analysis of Observational Studies. [in spa]. Arch Bronconeumol. 2017 Feb;53(2):55-61.Full text  Abstract

108. Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016 Sep;71(9):2397-404.Full text  Abstract

109. Classen AY, Henze L, von Lilienfeld-Toal M, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol. 2021 Jun;100(6):1603-1620.Full text  Abstract

110. Zhang G, Chen M, Zhang S, et al. Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia. Exp Ther Med. 2018 Feb;15(2):1594-1601.Full text  Abstract

111. Huang YS, Liu CE, Lin SP, et al. Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia. AIDS. 2019 Jul 1;33(8):1345-1351.Full text  Abstract

112. Wang M, Lang G, Chen Y, et al. A Pilot Study of Echinocandin Combination with Trimethoprim/Sulfamethoxazole and Clindamycin for the Treatment of AIDS Patients with Pneumocystis Pneumonia. J Immunol Res. 2019;2019:8105075.Full text  Abstract

113. Wickramasekaran RN, Jewell MP, Sorvillo F, et al. The changing trends and profile of pneumocystosis mortality in the United States, 1999-2014. Mycoses. 2017 Sep;60(9):607-15. Abstract

114. Dworkin MS, Hanson DL, Navin TR. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis. 2001 May 1;183(9):1409-12.Full text  Abstract

115. Arozullah AM, Yarnols PR, Weinstein RA, et al. A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1081-6. Abstract

116. Walzer PD, Evans HE, Copas AJ, et al. Early predictors of mortality from Pneumocystis jiroveci pneumonia in HIV-infected patients: 1985 to 2006. Clin Infect Dis. 2008 Feb 15;46(4):625-33. Abstract

117. Morris A, Creasman J, Turner J, et al. Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med. 2002 Aug 1;166(3):262-7. Abstract

118. Nickas G, Wachter RM. Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med. 2000 Feb 28;160(4):541-7. Abstract

119. Powell K, Davis JL, Morris AM, et al. Survival for patients with human immunodeficiency virus admitted to the intensive care unit continues to improve in the current era of highly active antiretroviral therapy. Chest. 2009 Jan;135(1):11-7. Abstract

120. Wachter RM, Luce JM, Safrin S, et al. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure. JAMA. 1995 Jan 18;273(3):230-5. Abstract

121. Wachter RM, Luce JM, Turner J, et al. Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis. 1986 Nov;134(5):891-6. Abstract

122. Wachter RM, Russi MB, Bloch DA, et al. Pneumocystis carinii pneumonia and respiratory failure in AIDS. Improved outcomes and increased use of intensive care units. Am Rev Respir Dis. 1991 Feb;143(2):251-6. Abstract

123. Morris A, Wachter RM, Luce J, et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS. 2003 Jan 3;17(1):73-80. Abstract

124. Mansharamani NG, Garland R, Delaney G, et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000 Sep;118(3):704-11. Abstract

125. Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med. 1995 Dec 11-25;155(22):2436-41. Abstract

126. Cao B, Wang H, Wang P, et al. Clinical parameters and outcomes of Pneumocystis jiroveci pneumonia in non-HIV/AIDS patients. Chin Med J (Engl). 2006 Feb 5;119(3):234-7. Abstract

127. Sepkowitz KA, Telzak EE, Gold JW, et al. Pneumothorax in AIDS. Ann Intern Med. 1991 Mar 15;114(6):455-9. Abstract

128. DeLorenzo LJ, Huang CT, Maguire GP, et al. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest. 1987 Mar;91(3):323-7. Abstract

129. Metersky ML, Colt HG, Olson LK, et al. AIDS-related spontaneous pneumothorax. Risk factors and treatment. Chest. 1995 Oct;108(4):946-51. Abstract

130. Dhasmana DJ, Dheda K, Ravn P, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs. 2008;68(2):191-208. Abstract

131. Lawn SD, Török ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis. 2011 Feb;24(1):34-42. Abstract